May 4, 2023 7:00 am EDT BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City
Apr 24, 2023 7:00 am EDT BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100
Mar 31, 2023 8:30 am EDT BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion
Mar 22, 2023 9:15 am EDT What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Mar 13, 2023 7:00 am EDT BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100
Mar 9, 2023 6:30 am EST BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Mar 7, 2023 6:30 am EST BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023
Mar 2, 2023 7:30 am EST BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
Feb 10, 2023 8:45 am EST BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes